Liver cancer patients get a second chance with combo therapy
NCT ID NCT07184424
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study looked at 24 adults with advanced liver cancer whose tumors continued to grow despite standard treatment with lenvatinib and a PD-1 inhibitor. Researchers added lenalidomide to see if it could help control the cancer again. The goal was to measure how long patients lived without their cancer getting worse and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.